Pharmaceutical Stocks are Gaining Momentum amid COVID-19 Vaccine Development
07.08.2020, 05:57

Pharmaceutical Stocks are Gaining Momentum amid COVID-19 Vaccine Development

The pharmaceutical industry is gaining momentum as many companies worldwide are seeking the cure from a deadly COVID-19 infection. U.S. President Donald Trump said the vaccine could be developed already by November this year. Many countries like Australia, Japan, South Korea have approved medications that will help infected to recover from the decease. Vaccine, when it appears on the market, will be of a great demand by most of the countries and would boost sales of medications worldwide. Pharmaceutical stocks have performed well since the beginning of last year posting gains of 14.7% compared to the S&P 500's total return of 14.3%, according to the SPDR S&P Pharmaceuticals ETF (XPH) research. 

Here are the three pharmaceutical stocks with the best value, fastest earning growth and the most momentum. 

Moderna has been one of the front-runners within the COVID-19 vaccine race. The company’s vaccine candidate mRNA-1273 could be a particle that heredity encodes a set of informational, based on which cells make proteins and send them to different parts of the body. Moderna’s immunization for COVID-19 appeared it was safe and activated safe reactions in all 45 healthy volunteers within the early-stage consider. Its shares have picked up 28.5% for the past month. 

Pfizer joined powers with German biotech mammoth BioNTech (NTX) to create an antibody for coronavirus. The company has  entered its stage 2/3 security and adequacy clinical consider on 30,000 subjects. Clinical trials has performed well so far and secured the company a $1.95 billion contract with up to 600 million doses of the vaccine to be delivered to the market. Pfizer’s shares have progressed 10.9% within the past month. The Zacks Agreement Research estimate  current-year profit has moved forward 1.4% over the past 60 days. Pfizer carries a Zacks Rank #3 (Hold). 

Gilead Sciences, Inc. GILD in May got an emergency-use authorization from the FDA based on the medication comes about from two clinical trials: one conducted by the NIAID and the other by itself. The company’s anticipated profit development rate for following year is 4.1%. The Zacks Agreement appraise for current-year profit has progressed 3.8% over the past 30 days. Shares of the company have picked up 9.7% year to date.

© 2000-2020. All rights reserved.

This site is managed by Teletrade D.J. Limited 20599 IBC 2012 (First Floor, First St. Vincent Bank Ltd Building, James Street, Kingstown, St. Vincent and the Grenadines).

The information on this website is for informational purposes only and does not constitute any investment advice.

AML Website Summary

Risk Disclosure

Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.

Privacy Policy

Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to teletrade.org. Automatic import of materials and information from this website is prohibited.

Please contact our PR department if you have any questions or need assistance at pr@teletrade.global.

Feedback
Live Chat E-mail
Up
Choose your language / location